Rafael Holdings, Inc. Share Price & Technical Analysis
RFL · $1.34 (+0.75%)
Real Estate / Real Estate Services
$1.34
+0.75%
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.…
Price chart
Seasonality
May has 0 positive and 3 negative years (last 5 years shown)
0% return in May, -4% avg return in past 3 year May month.
9% return in 2026, -4% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 8% | -8% | 8% | 0% | – | – | – | – | – | – | – | 9% |
| 25 | 18% | 0% | -5% | -11% | -7% | 13% | -6% | -12% | 0% | 0% | -14% | 0% | -24% |
| 24 | 0% | -6% | 0% | -6% | -6% | -7% | 7% | -7% | 27% | -5% | 6% | -11% | -8% |
| 23 | 11% | 0% | -29% | 40% | 0% | 5% | -5% | 10% | -14% | -5% | 0% | 6% | 20% |
| 22 | -18% | -26% | -19% | -16% | -10% | -5% | 5% | 5% | -14% | -6% | 6% | -5% | -104% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$68.14M
P/E ratio
—
52W high
$3.19
52W low
$1.12
Volume
12,038
Beta
0.49
Related stocks in Real Estate
Ventas Inc
₹1,475
Equinix, Inc.
₹1,086
Public Storage
₹311.6
Frequently asked questions
- What is Rafael Holdings, Inc. share price today?
- Rafael Holdings, Inc. (RFL) last traded around $1.34 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RFL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RFL. Download the app for real-time alerts.
- How can I analyze Rafael Holdings, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.